Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
van Moort I, Preijers T, Bukkems LH, Hazendonk HCAM, van der Bom JG, Laros-van Gorkom BAP, Beckers EAM, Nieuwenhuizen L, van der Meer FJM, Ypma P, Coppens M, Fijnvandraat K, Schutgens REG, Meijer K, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT study group. van Moort I, et al. Among authors: van der meer fjm, van der bom jg. Lancet Haematol. 2021 Jul;8(7):e492-e502. doi: 10.1016/S2352-3026(21)00135-6. Lancet Haematol. 2021. PMID: 34171280 Clinical Trial.
The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC, van Moort I, Fijnvandraat K, Kruip MJ, Laros-van Gorkom BA, van der Meer FJ, Meijer K, Peters M, Schutgens RE, Zwaan CM, Driessens MH, Polinder S, Leebeek FW, Mathôt RA, Cnossen MH. Hazendonk HC, et al. Among authors: van der meer fj, van moort i. Thromb Haemost. 2015 Aug 31;114(3):639-44. doi: 10.1160/TH14-11-0925. Epub 2015 Jun 11. Thromb Haemost. 2015. PMID: 26062822 Clinical Trial.
von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
van Moort I, Bukkems LH, Heijdra JM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Meer FJM, Fijnvandraat K, Ypma P, de Maat MPM, Leebeek FWG, Meijer K, Eikenboom J, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. van Moort I, et al. Among authors: van der meer fjm. Thromb Haemost. 2020 Jul;120(7):1056-1065. doi: 10.1055/s-0040-1710591. Epub 2020 Jun 1. Thromb Haemost. 2020. PMID: 32480417 Clinical Trial.
Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
van Moort I, Preijers T, Hazendonk HCAM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Meer FJM, Fijnvandraat K, Leebeek FWG, Meijer K, Mathôt RAA, Cnossen MH; OPTI-CLOT study group. van Moort I, et al. Among authors: van der meer fjm. Br J Clin Pharmacol. 2021 Jun;87(6):2602-2613. doi: 10.1111/bcp.14670. Epub 2020 Dec 16. Br J Clin Pharmacol. 2021. PMID: 33232535 Free PMC article.
Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?
Goedhart TMHJ, Bukkems LH, van Moort I, Spence CC, Zwaan MC, de Maat MPM, Mathôt RAA, Cnossen MH; OPTI-CLOT study group and SYMPHONY consortium. Goedhart TMHJ, et al. Among authors: van moort i. Haemophilia. 2022 Jul;28(4):610-618. doi: 10.1111/hae.14575. Epub 2022 May 8. Haemophilia. 2022. PMID: 35526235 Free PMC article. Clinical Trial.
Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
Preijers T, van Moort I, Fijnvandraat K, Leebeek FWG, Cnossen MH, Mathôt RAA; ‘OPTI-CLOT’ Study Group. Preijers T, et al. Among authors: van moort i. Thromb Haemost. 2018 Mar;118(3):514-525. doi: 10.1055/s-0038-1623531. Epub 2018 Mar 13. Thromb Haemost. 2018. PMID: 29534249
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM, Al Arashi W, de Jager NCB, Cloesmeijer ME, Bukkems LH, Zwaan CM, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. Heijdra JM, et al. BMJ Open. 2022 Feb 15;12(2):e049493. doi: 10.1136/bmjopen-2021-049493. BMJ Open. 2022. PMID: 35168962 Free PMC article.
One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients.
de Jager NCB, Bukkems LH, Heijdra JM, Hazendonk CHCAM, Fijnvandraat K, Meijer K, Eikenboom J, Laros-van Gorkom BAP, Leebeek FWG, Cnossen MH, Mathôt RAA; OPTI-CLOT group. de Jager NCB, et al. J Thromb Haemost. 2020 Feb;18(2):295-305. doi: 10.1111/jth.14652. Epub 2019 Oct 21. J Thromb Haemost. 2020. PMID: 31557387 Free PMC article.
26 results